Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population

Conclusion Elderly patients aged < 75 years were able to tolerate standard immunochemotherapy, with acceptable survival profiles. In an Asian population, 75 years seems to be a judicious cutoff for predicting treatment outcomes. Micro-Abstract We evaluated the real-life treatment outcomes of elderly patients with diffuse large B-cell lymphoma from an Asian population. The medical records of 192 patients aged > 60 years who had received first-line immunochemotherapy were retrospectively analyzed. Elderly patients < 75 years old tolerated standard immunochemotherapy, with acceptable survival profiles. In an Asian population, 75 years of age seems a judicious cutoff for predicting treatment outcomes.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research